- Home
- LX vs ABSI Comparison
LX vs ABSI Comparison
Compare LX & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.72
Company Overview
Basic Information| Metric | LX | ABSI |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.4M | 418.0M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LX | ABSI |
|---|---|---|
| Price | $2.88 | $2.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.50 | ★ $7.98 |
| AVG Volume (30 Days) | 1.2M | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.89% | N/A |
| EPS Growth | N/A | ★ 21.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | N/A | $10.72 |
| Revenue Next Year | N/A | $313.07 |
| P/E Ratio | $2.08 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.62 | $2.01 |
| 52 Week High | $11.64 | $5.23 |
Technical Indicators
Market Signals| Indicator | LX | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.29 | 45.46 |
| Support Level | $2.62 | $2.49 |
| Resistance Level | $3.10 | $2.89 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 46.25 | 73.31 |
Price Performance
Historical Comparison LX
ABSI
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.